As of 30 Sep 2025, 1 institutional investors reported holding 181,600 shares of MOONLAKE IMMUNOTHERAPEUTICS - COM (HLXA).
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 181,600 | $1,302,072 | $7.17 | 1 | |
| 2025 Q2 | 181,600 | $8,571,520 | +$472,000 | $47.20 | 1 |
| 2025 Q1 | 171,600 | $6,704,412 | $39.07 | 1 | |
| 2024 Q4 | 171,600 | $9,292,140 | +$270,750 | $54.15 | 1 |
| 2024 Q3 | 166,600 | $8,399,972 | $0 | $50.42 | 1 |
| 2024 Q2 | 166,600 | $7,325,402 | $0 | $43.97 | 1 |
| 2024 Q1 | 166,600 | $8,368,318 | +$8,368,318 | $50.23 | 1 |
| 2022 Q2 | 0 | $0 | -$116,190,949 | $7.17 | 0 |
| 2022 Q1 | 10,912,791 | $116,191,000 | -$3,240,025 | $11.10 | 26 |
| 2021 Q4 | 11,425,219 | $112,817,466 | +$259,021 | $9.89 | 45 |
| 2021 Q3 | 11,218,564 | $111,066,000 | -$425,888 | $9.89 | 43 |
| 2021 Q2 | 11,194,065 | $115,764,000 | +$5,400,491 | $10.35 | 45 |
| 2021 Q1 | 10,667,865 | $108,909,000 | -$2,638,139 | $10.20 | 42 |
| 2020 Q4 | 10,908,299 | $122,413,000 | +$109,677,015 | $11.37 | 44 |